New vaccine designed to boost COVID protection for vulnerable cancer patients
NCT ID NCT05672355
Summary
This study is testing whether a new COVID-19 booster vaccine (called GEO-CM04S1) works better than the current standard mRNA boosters for people with chronic lymphocytic leukemia (CLL), a type of cancer that weakens the immune system. The trial will enroll 80 adults with CLL who have already had their initial COVID-19 shots. Researchers will compare the two vaccines to see which one triggers a stronger and longer-lasting immune response against the virus over a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.